Conference Program November 6-8, 2020

CANO/ACIO 2020

Now and Forever Oncology Nursing World Health Organization The Year of the Nurse and the Midwife Les soins infirmiers en oncologie d’aujourd’hui et de demain Organisation mondiale de la Santé Année des infirmières et des sages-femmes ACCESS MANAGEMENT A FULLY INTEGRATED PROGRAM THAT DELIVERS END-TO-END CARE. At BD, we believe that truly effective vascular access therapy starts long before the first IV is ever inserted. That’s why we designed the BD® Vascular Access Management program: an integrated solution that spans the continuum of vascular access care. The program aims to help clinicians reduce complications and improve quality of care by standardizing on industry best practices throughout the entire process. With the combined expertise of BD and BARD—now as one BD—our program offers in-depth assessments, evidence-based recommendations, training and education, and world-class tools and technologies. Discover total vascular access management designed to deliver better clinical and economic outcomes. Discover the new BD.

Learn more at bd.com/TotalManagement

BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. BD-9535 (0419) The image depicted contains models and is being used for illustrative purposes only. Janssen Global Services, LLC. © JGS 2019

Some treatments manage cancer. We’re out to cure it. Our biggest goal is to stop cancer before it can adapt and evolve. That’s why we’re developing innovative personalized therapies, and other treatments to harness the body’s natural defenses. Everything we do gets us closer to a future where disease is a thing of the past. Learn more at www.janssen.com/canada.

vx200007_13-02_JAN-ONC-Ad_PNT_8.5x11_CA_EN.indd 1 2020-10-20 3:59 PM NOW REIMBURSED in most provinces (criteria apply)*

Visit venclextareimbursement.ca CONFRONT R/R CLL WITH to find out more! PrVENCLEXTA® + RITUXIMAB1

In an open-label study, VENCLEXTA + rituximab demonstrated superior PFS compared with bendamustine + rituximab1†

• 81% reduction in instantaneous risk of progression or death vs. bendamustine + rituximab (HR: 0.19 [95% CI: 0.13‑0.28]; p<0.0001).1 • The 2‑year rates of PFS for the VENCLEXTA + rituximab and bendamustine + rituximab arms were 82.76% (95% CI: 76.62‑88.90) and 39.42% (95% CI: 31.03‑47.82), NCCN Guidelines‡ Category 1 recommendation: respectively (IRC‑assessed in the ITT Venetoclax + rituximab is recommended as a preferred regimen for R/R CLL3 population).1,2

Indication and clinical use: • Neutropenia; dose interruption/reduction For more information: VENCLEXTA (venetoclax) in combination with rituximab recommended for severe neutropenia; prophylactic use Please consult the Product Monograph at is indicated for the treatment of adult patients with CLL who of growth factors (e.g. G-CSF) may be considered. abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/ have received at least one prior therapy. • Immunization using live vaccines should be avoided products/VENCLEXTA_PM_EN.pdf for important information No safety and efficacy data for VENCLEXTA in children during treatment and thereafter until B-cell recovery. relating to adverse reactions, drug interactions and dosing and adolescents below 18 years of age are available. • Monitor for signs of infection and have their complete information which have not been discussed in this piece. blood counts monitored throughout treatment. The Product Monograph is also available by calling Contraindication: • Recommended dose not determined for patients 1-888-704-8271 or 514-906-9771. Concomitant use with strong CYP3A inhibitors at initiation with severe renal impairment (CrCl <30 mL/min) or * VENCLEXTA is currently listed as an exception benefit on the formulary of and during ramp-up phase. the following provinces: Alberta (Outpatient Cancer Drug Benefit Program), on dialysis. British Columbia (BC Cancer – Compassionate Access Program), Manitoba • Females of reproductive potential: test to exclude (Cancer Care Manitoba), New Brunswick (New Brunswick Prescription Drug Most serious warnings and precautions: pregnancy before treatment; use of effective Plan), Nova Scotia (Nova Scotia Formulary Updates), Ontario (Cancer Care • VENCLEXTA should only be prescribed by Ontario), Saskatchewan (Saskatchewan Cancer Agency) and Quebec (Liste contraceptives during treatment and for at least 30 days des médicaments – établissements). a qualified physician who is experienced after last dose. † Based on results from a randomized (1:1), multicentre, open-label, Phase 3 in the use of anti-cancer agents. • Male fertility may be compromised. study that evaluated the efficacy and safety of VENCLEXTA in combination with rituximab versus bendamustine in combination with rituximab in • VENCLEXTA is only available through specialty • Avoid use during pregnancy. pharmacies and/or retail oncology pharmacies patients with relapsed/refractory CLL who had received at least one line • Breastfeeding should be discontinued. of prior therapy. Patients previously treated with VENCLEXTA were excluded. that are part of AbbVie’s managed Patients in the VENCLEXTA + rituximab arm completed the 5-week ramp-up distribution program. • No overall difference in effectiveness and safety observed schedule of VENCLEXTA and received 400 mg VENCLEXTA daily for 24 months • Tumour lysis syndrome (TLS) in patients ≥65 years of age compared to younger from Day 1, Cycle 1 of rituximab in the absence of disease progression or patients. In the combination study (MURANO), patients unacceptable toxicity. After the 5-week dose ramp-up, rituximab was initiated at 375 mg/m2 for Cycle 1 and 500 mg/ m2 for Cycles 2-6. Each cycle was Weekly dosage ramp-up over a period of 5 weeks, ≥65 years of age experienced higher incidences of with blood chemistry monitoring on each dose 28 days. Patients randomized to bendamustine + rituximab received diarrhea, peripheral oedema, dizziness, blood creatinine bendamustine at 70 mg/ m2 on Days 1 and 2 for 6 cycles and rituximab at the ramp-up is required. increased, constipation, pyrexia and fall than those above described dose and schedule. Following completion of the 24-month Patients must receive prophylaxis for TLS, <65 years of age. treatment in the VENCLEXTA + rituximab arm or 6 cycles of bendamustine + including hydration and anti-hyperuricemics rituximab, patients continued to be followed for disease progression and • Patients with hepatic impairment should be monitored overall survival. A total of 389 patients were randomized; 194 to the prior to initiating treatment. more closely for signs of toxicity. VENCLEXTA + rituximab arm and 195 to the bendamustine + rituximab arm. Concomitant use of strong CYP3A inhibitors R/R: relapsed/refractory; CLL: chronic lymphocytic leukemia; at initiation and during ramp-up phase Severe hepatic impairment: A 50% reduction PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; is contraindicated. in VENCLEXTA dose is recommended throughout ITT: intention-to-treat; IRC: independent review committee; NCCN: National ‡ the initiation, ramp-up phase and steady state Comprehensive Cancer Network ; G-CSF: granulocyte-colony stimulating • Serious infections that may lead to factor; CrCl: creatinine clearance. once daily dose. hospitalization or death. References: 1. VENCLEXTA Product Monograph. AbbVie Corporation. • Monitoring and laboratory tests: tumour burden April 27, 2020. 2. 2-year PFS estimate data. Data on File. AbbVie Corporation. Other relevant warnings and precautions: 3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines‡). Chronic assessment; blood chemistry monitoring; signs Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2020. • Second primary malignancies: monitor patients of infection; complete blood counts; baseline renal December 20, 2019. for the appearance of non-melanoma skin cancers. function and hepatic status. ‡ All other trademarks are the property of their respective owner(s).

abbvie.ca 1-888-703-3006 Printed in Canada © AbbVie Corporation VEN/156A – August 2020

VEN20110_VEN156A_Venclexta_CurrentOnc_JAd_8.5x11_E_m1.indd 1 2020-08-26 2:44 PM Place crop marks at -0p9 at marks crop Place

Brands. Generics. Biosimilars. Pr TRUXIMA ® is the first Rituxan® (rituximab) biosimilar and has been available to Canadians since 20191,2*

Rituximab for Injection 10 mg/mL Intravenous Infusion

Biosimilar by design. Biologic by essence.

Creative representation of a molecule.

Non-Hodgkin’s Lymphoma (NHL)2†‡ Chronic Lymphocytic Leukemia (CLL)2‡ TRUXIMA® (rituximab for injection) is indicated for the TRUXIMA® (rituximab for injection) is indicated for treatment of patients with previously untreated Stage the treatment of patients with previously untreated III/IV follicular, CD20 positive, B-cell non-Hodgkin's or previously treated B-cell chronic lymphocytic lymphoma in combination with CVP (cyclophosphamide, leukemia (B-CLL), Binet Stage B or C, in combination vincristine and prednisolone) chemotherapy. with fludarabine and cyclophosphamide.

Pr TRUXIMA®: A proud offering TRUXIMA® has been available from Teva Canada Innovation. in the EU since 2017.3,4* Rituximab for Injection 10 mg/mL Intravenous Infusion For more information: Please consult the Product Monograph at https://www.tevacanada.com/globalassets/ Pr canada-ph2/pdf-documents-en/specialty-pdfs/0620_truxima_pm_en.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, administration (administered as an intravenous [IV] infusion through a dedicated line, not administered as an IV push or bolus) and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is Rituximab for Injection also available by calling Teva Canada Innovation at 1-833-662-5644. 10 mg/mL Intravenous Infusion

* Comparative clinical significance is unknown. † Please refer to the TRUXIMA® Product Monograph to see the complete list of NHL indications. ‡ Indications have been granted on the basis of similarity between TRUXIMA® and the reference biologic drug Rituxan®. EU: European Union. References: 1. Data on File. First to market rituximab biosimilar. Teva Canada. May 31, 2019. 2. TRUXIMA® Product Monograph. Teva Canada Limited. May 22, 2020. 3. IQVIA. Summary of study results. June 27, 2019. 4. Data on File. Letter of attestation for EU indications of TRUXIMA®. July 9, 2019.

Rituxan® is a registered trademark of IDEC Pharmaceuticals Corporation, used under license. PrTRUXIMA® a registered trademark of Celltrion Healthcare Co., Ltd. 08/2021 © 2020 Teva Canada Innovation G.P. – S.E.N.C. Montreal, Quebec, H2Z 1S8 TRU20-ADH04E

BIO20167_TRU20-ADH04E_Truxima HCP Journal Ad_8.5x11_E_m2.indd 1 2020-08-05 12:05 PM Congratulations to the nominees of the 2020 Boehringer Ingelheim Oncology Nurse of the Year Award! Toutes nos félicitations aux candidat(e)s au prix Boehringer Ingelheim de l'inﬁrmier(ère) de l’année pour 2020!

Kim Chapman, Fredericton, NB Sydney Farkas, Rocky View County, AB Margaret Forbes, Hamilton, ON Laurie Ann Holmes, Ottawa, ON Katie Nichol, Ottawa, ON Krista Rawson, Calgary, AB

Le prix sera remis lors de la cérémonie annuelle de The award will be presented at the annual Awards remise des prix d'excellence à la conférence virtuelle of Excellence Ceremony at the CANO/ACIO 2020 CANO / ACIO 2020 le vendredi 6 novembre 2020 de Virtual Conference on Friday, November 6, 2020 19 h 00 à 20 h 30 HNE. from 7:00pm – 8:30pm EST. Encore une fois, toutes nos félicitations et nos meilleurs Congratulations and best wishes to all nominees. voeux à l’ensemble des candidates et candidats.

CANO/ACIO gratefully acknowledges the generous support of Boehringer Ingelheim (Canada) for this award

L’ACIO/CANO tient à remercier Boehringer Ingelheim (Canada) du généreux soutien fourni envers ce prix. G NIZIN COG CIO THE CANO/ACIO AWARDS RE CEREMONY IS SCHEDULED FOR Friday, November 6, 2020 from CANO/A 7:00pm – 8:30pm EST ARS during the CANO/ACIO 2020 ST Virtual Conference

At the ceremony we will recognize the extraordinary contributions of our members to their profession, their patients, and their community.

THE FOLLOWING AWARDS WILL BE PRESENTED: Boehringer Ingelheim Oncology Nurse of the Year Award Pfizer Award for Excellence in Nursing Leadership Pfizer Award for Excellence in Nursing Clinical Practice CANO Research Grant CANO Lifetime Achievement Award CONJ Editor’s Award of Excellence

OUR TWO LECTURESHIP AWARDS WILL BE PRESENTED IN THE FOLLOWING SESSIONS: Saturday, November 7, 2020 from Sunday, November 8, 2020 from 2:05pm – 2:55pm EST 12:30pm – 1:20pm EST Sponsored by CANO/ACIO Sponsored by Merck

CANO/ACIO CHAPTER POSTER AWARDS! Sponsored by the Alberta South, British Columbia, Ontario-Champlain, Ontario-Toronto, PEI, Nova Scotia, Quebec, & Saskatchewan

We wish to thank members for the leadership shown in nominating one of their colleagues for an award. And, we wish to thank the sponsors of the awards. CANO/ACIO 2020

Table of Contents Sponsor and Exhibitor Listing...... 10 Welcome from the President...... 13 Committee Listing...... 16 Chapter Executives...... 19 Continuing Nursing Education (CNE)...... 22 Program...... 23 Abstract Posters...... 27

8 Remote symptom monitoring has never been more critical for cancer patients

Noona® is a patient outcomes management solution designed to support oncology care teams with clinical decision making in symptom monitoring and outcomes management for patients who are living with cancer. Noona enables clinics to remotely address the needs of patients who may be immunocompromised and reduce their exposure to clinical environments.

For more information: www.varian.com/noona

Engage Patients Decrease Resource Preserve Patient Health Keep patients engaged Utilization Symptom management may in their care and improve Reduce avoidable ER visits provide a better quality of life for their overall experience or hospitalizations patients living with cancer

Canada_halfpageNoonaad.indd 1 10/21/20 10:47 AM CANO/ACIO 2020

Sponsor and Exhibitor Listing The 2020 CANO/ACIO Annual Conference – The Virtual Edition is made possible by the generous support of the following organizations: PLATINUM

GOLD

SILVER

GAMIFICATION SPONSOR

SYMPOSIA • AstraZeneca Canada Inc. • BD • Janssen • LEO Pharma

FOCUS GROUPS • AstraZeneca and Merck Canada • Elvium Life Sciences • Jazz Pharmaceuticals • Mylan

AWARD SPONSORS • Boehringer Ingelheim • Pfizer• Merck Canada • CANO/ACIO

EXHIBITORS • AbbVie • Amgen • Apobiologix • Association of Pediatric Hematology/Oncology Nurses • AstraZeneca and Merck Canada • AstraZeneca Canada Inc. • BD • Bristol Myers Squibb Canada • CardioMed Supplies Inc. • Eisai Canada • Eli Lilly Canada Inc. • Elvium Life Sciences • GlaxoSmithKline Inc. • Innovative OncoSolutions • Ipsen Canada • Janssen • Jazz Pharmaceuticals • Kite, A Gilead Company • Leo Pharma • Look Good Feel Better • L’Oreal Canada • Mylan • Pfizer • Roche • Sanofi Genzyme • Taiho • Takeda • Teva Canada • Varian Medical Systems

10 LYNPARZA and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. © AstraZeneca 2020 LYNPARZA et le logo d’AstraZeneca sont des marques déposées d’AstraZeneca AB, utilisées sous licence par AstraZeneca Canada Inc. © AstraZeneca 2020 CA-1827 MERCK® is a registered trademark of Merck Canada Inc. MERCK ® et une marque déposée Merck Canada inc.

LYNPARZA-LetterSize.indd 1 10/26/2020 11:18:31 AM What Science Can Do

At AstraZeneca, we believe in the power of what science can do to transform serious diseases like cancer, heart disease, diabetes, COPD and asthma. Each and every one of us is bold in the belief that science should be at the centre of everything we do. It compels us to push the boundaries of what is possible. To trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease. Together we can develop creative solutions to help tackle the challenges of effectively preventing and treating disease. AstraZeneca Canada Inc. is proud of our commitment to support Canada’s healthcare community.

Oncology combination therapies AstraZeneca is investigating combinations of biologic and small-molecule therapies for the treatment of cancer. These combinations target the tumour directly and some help boost the body’s immune system to induce cell death.

The AstraZeneca logo is a registered trade-mark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

AZ_CorpAd-Science-8.5x5.5.indd 1 10/22/2020 11:27:21 AM Innovation Collaboration Solutions

LIFE SUSTAINING SOLUTIONS Evidence based strategies to optimize VAD outcomes with COVID patients Punctur Guard SecurAcath Prevent Blood Reﬂux Reduces catheter-related www.cardiomed.com infections and decreases catheter dislodgements www.securacath.com

Surefuser + Lightweight, closed system with built-in-safety features. www.cardiomed.com

StatSeal Leaderflex StatSeal instantly creates a Prevent Multiple Needlesticks seal over the procedural site to www.leaderflex.com stop the flow of blood and exudates. Evidence-based strategies to enhance patient www.statseal.com safety duringthe challenges of COVID care CANO/ACIO 2020

Welcome from the President Dear Colleagues, On behalf of the CANO/ACIO Board, I am honoured to welcome you to our 32nd Annual CANO/ACIO Conference and our first ever Virtual Conference. Our conference theme this year, “Now and Forever Oncology Nursing”, highlights both the importance and longevity of our commitment to cancer care. This historic year, 2020, has also been declared the “Year of the Nurse and the Midwife” by the World Health Organization. I feel that it has never been more apparent how vital a role that nurses play in the health and well-being of people throughout the world, from time of birth through to death. When I think back to our conference in Winnipeg last year, I am struck by how relatively carefree I had been at the time. I am certain that I was worried about my presentations and wanting to ensure the content was accurate and relevant (and I was also probably a little worried about tripping on stage, which I did at the 2016 conference in Calgary!) And now, the world looks quite different on so many fronts. In the span of a year, we have experienced significant change as we find ourselves 10 months into a global pandemic, having witnessed profound loss of life and unimaginable suffering. At time of writing this letter, we have reached a grim milestone, with over 10,000 Canadians having lost their lives to COVID-19. The impact of COVID-19 is far-reaching and in addition to loss of life and the resultant grief, there are many consequences of COVID-19 that may not be fully realized for years to come. There will be a special session that will address the impact of COVID-19 on cancer care, “Cancer and COVID-19: Challenges and Opportunities”, on Saturday, November 7 from 5pm-6pm EST, just prior to our Annual General Meeting. We welcome everyone to attend our Annual General Meeting as the Board shares the work that has been done over the past year to achieve the goals established in our Strategic Plan (2017-2021) and looks ahead to 2021 and the development of our next Strategic Plan. The Annual General Meeting also serves as a forum for members to express their ideas and hopes for how to move the Association forward. We need and value your participation and voice. In addition to the challenges presented by the pandemic, in 2020 we have also borne witness to extreme examples of racism and structural violence. In September, hearing of the horrific final moments and subsequent death of Joyce Echaquan, a 37 year-old Atikamekw mother of 7 children, I found myself silently screaming, “Not in Canada!! And not nurses!!” The reality that such insidious racism could pervade healthcare in Canada was frankly nauseating and I wanted with every ounce of my being to wish it were not true. And yet I know it is true. Dr. Sally Thorne recently wrote, “We need to shake our collective selves free of that convenient illusion that we are off the hook because we know ourselves to be kind, compassionate, and professional in all of our patient interactions regardless of race or privilege. That is simply no longer enough” (Thorne, 2020, pp. 1-2). Throughout the past year, Dr. Thorne has written about issues germane to nursing through the pandemic as well as has addressed the topic of inherent systemic racism in healthcare and in society more broadly. We are honoured and elated that Dr. Thorne will present our keynote address, “Nursing in Uncertain Times: The “Art” of Being a Nuisance” on Saturday, November 7, from 12:05pm-12:55pm EST.

13 CANO/ACIO 2020 Welcome from the President

In oncology nursing, there is no question that significant progress has been and continues to be made. Oncology nurses have unequivocally been part of the successes in cancer care and indeed, play an integral role in current and future progress. And yet, nurses know that there is still a lot of work to be done. We know that cure does not always mean eradication of suffering and that while one might survive cancer, they may be left with an array of long-term side effects and complications that impact their physical, psychosocial, and spiritual well-being for years beyond the treatment of the cancer. We also know that more needs to be done to improve care for underserved populations such as (but not limited to): people with advanced or metastatic disease, Indigenous peoples, sexual and gender minorities, adolescents and young adults with cancer, adult survivors of pediatric cancer, and people who reside in rural and remote locations. We know that there are many people in Canada, and beyond our borders, who do not have access to quality, comprehensive cancer care, including palliative oncology care. Many of our conference sessions and workshops will address these topics and more. Without question, one of the highlights of any conference that I attend is the networking that occurs and the inevitable connections and friendships that are forged. This year, in spite of not being able to gather in person, we are fortunate to have the opportunity to connect virtually. We are hopeful that this virtual approach will afford an opportunity to those who have not been able to attend our conference in the past. Conference content will remain archived for six months, allowing participants the opportunity to view content at their leisure. A virtual event removes the expense and time required for travel. Our hope is that the conference content will be accessible to more nurses, including those with an interest in cancer care, within Canada and internationally. I would like to thank the Conference Planning Steering Committee, the Local Planning Committee, the Scientific Program Committee, the Recognition of Excellence Committee, and the Board of Directors for all of their hard work and efforts leading up to the conference. Special thanks to all at Malachite Management and especially Dana Cooper, Carla Kmet, and Ernest Ho for their tireless efforts in support of this event. Thank you to all of our industry sponsors, partners, and exhibitors. We are indebted to you all for your support. And thanks to each and every one of you who participates in our conference, either as a speaker or as an attendee. Our conference would not be possible without your involvement. In closing, as I envision you all swapping suitcases and airplanes for computer screens (and maybe even pyjamas, there’s no judgment!), I want to remind you of words of the late Justice Ruth Bader Ginsburg who said, “So often in life, things that you regard as an impediment turn out to be great, good fortune”. As an oncology nursing community, we may be required to be 6 feet apart but we remain inexorably intertwined. Physically distant, but always professionally, compassionately, and socially connected. On behalf of the Board of Directors, it is our sincere wish that you enjoy our virtual conference and that you find ways to connect with one another. Please reach out to any of us on the Board if we can be of help or even if you just want to chat. Finally, I read an article recently in Healthy Debate by Anne Borden King who asks in the title, “I’ve got cancer. Will I get the care I need during a pandemic?”. My answer, our collective answer, is: pandemic or not, oncology nurses are here for you…Now and Forever. With much gratitude and respect,

Sincerely,

Reanne Booker, MN BScN, NP President, CANO/ACIO

14 Ask about Akynzeo® formulary coverage (special authorization)

In combination with dexamethasone, Akynzeo® is a one capsule-per- chemotherapy-cycle treatment

Akynzeo® (netupitant/palonosetron) in combination with dexamethasone, is indicated for once-per-cycle treatment in adult patients for: • Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy • Prevention of acute nausea and vomiting associated with moderately emetogenic

cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone

Consult the product monograph at purdue.ca/en/products/Akynzeo-PM for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The product monograph is also available by calling Purdue Pharma at 1-800-387-5349.

Akynzeo® is a registered trademark of Helsinn Healthcare SA used under license by Purdue Pharma. Distributed under license of Helsinn Healthcare SA, Switzerland. © 2020 Purdue Pharma. All rights reserved.

CA-NTP-0758E

1417 Kite CorporateHalfPg_ad_8.5x5.5_102220_JF.indd 1 2020-10-22 4:27 PM CANO/ACIO 2020

Committee Listing CONFERENCE PLANNING STEERING SPECIAL INTERESTS GROUP COMMITTEE Jodi Hyman, RN, BScN, CONc Simonne Simon, MN, CON(C), CPSC Co-Chair Lisa Henczel, RN, BScN, MSN, NP(F) Margaret Fitch, RN, PhD, CPSC Co-Chair Cody Watling, MSc Andrea Knox, RN, BSN, CON(C), 2020 SPC Chair Michelle Ellwood, RN Michelle Lafreniere, RN, BScN, 2020 LPC Co-Chair Cationa (Trina) Buick, RN, PhD Senz Hamilton, RN, 2020 LPC Co-Chair Kari Kolm, RN(EC), MN, NP Jodi Hyman, RN, BScN, CON(C), 2019 LPC Co-Chair Kristine Leach, RN(EC), MN, CON(C) Rose Woloshyn, RN, BN, 2019 LPC Co-Chair Marcia Flynn-Post, RN, BA, MHS, CON(C) Michelle Rosentreter, RN, BN, CON(C), 2019 SPC Co-Chair Leslie Marvell, RN, BScN, CHPCN(c ), CON(C) Barbara Hues, RN, MSN, CON(C), 2019 SPC Co-Chair Janice Chobanuk, RN, BScN, MN, CON(C), CON(C) Leslie Maskell, BA, RN, BScN, Con(C), 2021 LPC Co-Chair Ruby Gidda, RN, BScN, M.ED. Heidi Thomas, RN, BScN, CON(C), 2021 LPC Co-Chair Zenith Poole, RN, CHPCN Janny Proba, RN, BScN, MEd(C), CON(C), CHPCN(C), CVAA(C), Jennifer Anderson, RN, MN, CON(C) 2021 SPC Co-Chair Lorelei Newton, PhD, RN Cheryl Page, RN, BSN, BSc, CON(C), BMTCN, 2021 SPC Co-Chair Fay Strohschein, RN, PhD Corsita Garraway, RN(EC),BScN, MScN CANO/ACIO BOARD OF DIRECTORS Amber Killam, RN, MScN, CON(C) Renata Benc, BA, MSc(A)N, CON(C) Reanne Booker, RN, BScN, MN, NP Anita Long, RN, MSN/ED, CON(C) President / Présidente Tracyann Machado Simonne Simon, RN, MN, CON(C) RN, BScN, MN Treasurer / Trésorière Carrie Liska, Sarah Champ, MN, RN, CON(C) Karine Bilodeau, RN, BScN, MScN, PhD CON(C) Director–at–Large – Education / Conseillère générale, education Carrie McDonald-Liska, RN, BScN, MN Kara Jamieson, RN, MN, MEd, CON(C) Director–at–Large – Communications / Conseillère générale, communications RECOGNITION OF EXCELLENCE Maurene McQuestion, RN, BA, BScN, MSc, CON(C) COMMITTEE Director–at–Large – External Relations / Conseillère générale,relation extérieures Jodi Hyman, RN, BScN, CON(C) Karen Janes, RN, BScN, MScN (Chair) Director–at–Large – Membership / Conseillère générale, adhesion Colleen Campbell, NP, MN, CON(C) Christine Maheu, RN, PhD Joy Tarasuk, RN, BScN, MN, CON(C) Director–at–Large – Research / Conseillère générale, recherché Lori Butts Margaret Fitch, RN, PhD Catherine Fox, MN, RN, CON(C) Canadian Oncology Nursing Journal Editor–in–Chief / Revue canadienne de Kassie Nguyen, RN soins infirmers en oncologie, éditeur en chef Samantha Scime, RN, MN, CON(C) Director-at-Large, Professional Practice /Conseillère générale entrant, pratique COMMUNICATIONS profesionnelle Kara Jamieson, RN, MN, MEd, CON(C) Lorelei Newton, PhD, RN Habeeba Akbari Incoming Vice-President / Vice-présidente entrant Catherine Fox, MN, RN, CON(C) Andrea Knox, RN, BSN, MSN, CON(c) Incoming Director–at–Large – External Relations / Conseillère générale entrant, Zoe Ignacio, RN, BN, CON(C) relation extérieures Jodi Hyman, RN, BScN, CON(C) Allyson Nowell, RN, MSc, CON(C) Vanessa Pagtakhan, RN, BScN

16 CANO/ACIO 2020

RESEARCH EDUCATION PROFESSIONAL PRACTICE

Christine Maheu, RN, PhD Sarah Champ, MN, RN, CON(C) Samantha Scime, RN, MN, CON(C) Aronela Benea, RN, BScN, MScN Lori Butts Jill Bullock, RN, BScN, MN CON(C) Jill Bally, RN, PhD Jeevan Dosanjh, RN, BScN Audrey Chouinard Joanne Crawford, RN, BScN, MScN, CON(C), PhD Stephanie Healey, RN, MN, CON(C) Sydney Farkas, RN, MN, CON(C) Jacqueline Galica, RN, MSc, PhD, CON(C) Cynthia Heron, RN, BScN, CON(C) Marcia Flynn-Post Kristen Haase, RN, PhD Laurie Ann Holmes, RN, BScN, CON(C), CHPCN(C) Catherine Fox, MN, RN, CON(C) Leah Lambert, RN, PhD Jodi Hyman, RN, BScN, CON(C) Nathalie Godin, RN, BA, MHS, CON(C) Virginia Lee, RN, PhD Kara Jamieson, RN, MN, MEd, CON(C) Terri Gray, BScN, CON(C) Manon Lemonde, PhD, RN, CON(C) Lynn Kachuik, RN, BA, MS, CON(C), CHPCN(C) Lynne Jolicoeur, RN, MScN, CON(C) Marian Florence Luctkar-Flude, RN, BScN, Karey McCann, BScN Leslie Marvell, RN, BScN, CHPCN(C), CON(C) MScN, PhD, CCSNE Natasha Olesen, RN, BScN Kassie Nguyen Tracy Powell, BScN, RN, MN, PhD(c) Cheryl Page, RN, BSN, BSc, CON(C), BMTCN Cheryl Page, RN, BSN, BSc, CON(C), BMTCN Sally Thorne, RN, PhD Jennifer Pesut, RN, BScN Jennifer Stephens, MA, PhD, RN, OCN Suganya Vadivelu, RN, BScN, MScN, CON(C), PGDHM Andrea Wong, RN, BScN Pat Yuzik, RN, MN, CON(C)

ARE YOUR PATIENTS SUFFERING FROM ONCOLOGY TREATMENTS? SO IS THEIR SKIN. Learn more about skin toxicities related to oncology treatments by visiting the La Roche-Posay virtual booth.

17 60% of women who benefit from 60% des femmes qui bénéficient Look Good Feel Better® are referred de Belle et bien dans sa peauMD en by their oncology nurse. Thank you for ont entendu parlé par leur équipe en referring your patients. Together, we oncologie. Merci de nous recommander can help women facing cancer feel like à vos patientes. Ensemble, nous aidons themselves again. les femmes atteintes de cancer à se sentir de nouveau elles-mêmes.

LGFB.CA | BBDSP.CA | @LGFBCanada

REG CHARITY #13374 0316 RR0001.

Pr ®

Supporting inner strength FULPHILA®, a pegﬁlgrastim biosimilar to decrease the incidence of infection, as manifested by febrile neutropenia from some cancer treatment(s).

AVAILABLE FOR YOUR PATIENTS!

For more information on the Mylan AdvocateTM patient support program, visit fulphila.ca

Indications and clinical use: Potential effect on malignant cells Fulphila (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile Aortitis neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Capillary leak syndrome (CLS) The safety and effectiveness of Fulphila in pediatric patients (<18 years of age) have not been established. Cutaneous vasculitis Severe sickle cell crises in patients with sickle cell trait or sickle cell disease Contraindications: Leukocytosis Hypersensitivity to E. coli-derived proteins‚ pegfilgrastim‚ filgrastim, or any other component of the product Hypersensitivity Most serious warnings and precautions: A complete blood count (CBC) and platelet count should be performed prior to administration of chemotherapy Splenic rupture: including fatal cases Regular monitoring of hematocrit value, white blood cell count and platelet count is recommended Severe sickle cell crises: associated with use in patients with sickle cell trait or sickle cell disease Glomerulonephritis Acute respiratory distress syndrome (ARDS) Other relevant warnings and precautions: Not recommended in pregnant or nursing women Should not be used for peripheral blood progenitor cell (PBPC) mobilization Splenic rupture For more information: Caution against simultaneous use with cytotoxic chemotherapy; should not be administered in the Consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for more period between 14 days before and 24 hours after administration of cytotoxic chemotherapy information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, Not studied in patients receiving chemotherapy associated with delayed myelosuppression, interactions and dosing. The Product Monograph is also available by calling 1-844-596-9526. mitomycin C, myelosuppressive doses of anti-metabolites, or radiation

FULPHILA® is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Mylan company. Mylan® is a registered trademark of Mylan Inc., used under permission by BGP Pharma ULC, a Mylan company. Copyright © 2020 BGP Pharma ULC, a Mylan company. All rights reserved. 85 Advance Road, Etobicoke, Ontario, M8Z 2S6 mylan.ca 1-844-596-9526 PEG-2020-0276E – OC2020

Fulphila_Ad 8.5 x 5.5 C M Y K CANO/ACIO 2020 Committees & Executives

Chapter Executives BC CHAPTER SASKATCHEWAN CHAPTER Andréanne Chevrette, Conseillères – Activités éducatives Andrea Knox, President, Membership & Shauna Houshmand, President Marie-Ève Bélanger, Conseillères – Activités Communications Chair Lina Esmail, Vice-President éducatives Michelle LaFreniere, Past President Meighan Kozlowski, Treasurer Alexis Parent, Communication externe / Site web Karen Janes, Secretary Patricia Yuzik, Secretary et Facebook Senz Hamilton, Treasurer Annie Jean, Communication externe / Site web et Scott Beck, Member at Large MANITOBA CHAPTER Facebook Naureen Mukhi, Member at Large Gabrielle Chartier, Représentants du comité Lorelei Newton, Member at Large Jodi Hyman, President organisateur de la conférence annuelle Michelle Rosentreter, Vice-President Jacinthe Brodeur, Représentants du comité NORTHWEST TERRITORIES Kathy Ramesar, Treasurer organisateur de la conférence annuelle CHAPTER Zoe Ignacio, Secretary, Scholarship’s Chair Billy Vinette, Représentants du comité Jordana Jones, Editor & Publisher of the Oncologic organisateur de la conférence annuelle Catherine Dixon, President Dencia Jean-Paul, Conseillères Julie Jones, Vice President/Treasurer ONTARIO–HORSESHOE Audrey Chouinard, Conseillères June Bartlett, Secretary Christine Maheu, Conseillères CHAPTER Maude Hébert, Représentante de la ville de ALBERTA NORTH CHAPTER Heidi Thomas, President Trois-Rivières Cheryl Page, Vice President Marie-Ève Bélanger, Représentante de la ville de Québec Karey McCann, President Janny Proba, Secretary Vanessa Pagtakhan, Co Vice-President Leslie Maskell, Treasurer Jaymi Rumsey, Co Vice-President NEW BRUNSWICK-MONCTON Romeo Felix, Treasurer ONTARIO–GREATER TORONTO CHAPTER Jessica Truong, Secretary CHAPTER Carolyn DeVito, President Michelle Lack, Education Sub-Committee Jenna McDougall, Vice-President Bonnie Harrison, Education Sub-Committee Shawne Gray, President Laura Booth, Treasurer Sarah Magega, Education Sub-Committee Philiz Goh, Past President Andrea Rose, Secretary Vanessa Pagtakhan, Social Media Coordinator Kylie Martin, Director of Communications Michael Harding, Members at Large Sanober Firth, Director of Finance Derek Rothe, Members at Large Sonali Kirshenbaum, Newsletter Editor In Chief PEI CHAPTER Rae-Lee Christie, Members at Large Kassie Nguyen, Events Coordinator Lisa Bishop, President Fiona Mitchell, Members at Large Marcia Flynn-Post, Member at Large Kara McQuid-Duffy, Past President Sarah Champ, Members at Large Tracyann Machado, Member at Large Lindsay McIver, Vice-President Rachelle Paquette, Student Representative Elaine Smith, Treasurer ALBERTA SOUTH CHAPTER Noreen Landrigan, Treasurer ONTARIO–CHAMPLAIN Janet Sharpe, Secretary Tammy Patel, President CHAPTER Rachel Ramsay, Vice-President Jennifer Anderson, Past President Janelle Desjardins, President NOVA SCOTIA CHAPTER Michael Strocel, Treasurer Amber Killam, Vice-President Kara Jamieson, President April Boychuk, Industry Liaison Vicky Samuel, Treasurer Heather Brander, Vice President Sarah Quinn, Industry Liaison Sara Olivier, Secretary Jeannie Kennedy, Treasurer Stephanie Ly, Student Representative & Social Margaret Woods, Secretary Media Coordinator QUEBEC CHAPTER Marwa Al-Alawi, Student Representative & Social Media Coordinator Maryse Carignan, Présidente NEWFOUND & LABRADOR Marika Swidzinski, Conseillère - Liaison CANO/ACIO CHAPTER Linda Hershon, Vice-Présidente Bernadine O’Leary, President Jacinthe Brodeur, Trésorière Billy Vinette, Secrétaire 19 We are in the business of breakthroughs—the kind that transform patients’ lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we’ll never give up our search for more hope, for more people, around the world.

Visit bms.com/ca to see how we’re bringing a human touch to everything we do.

Visit LIBTAYO.ca † Comparative clinical significance unknown.

® ConsiderPD-1 the Blockade demonstratedPD-1 Blockade in Cutaneous in Cutaneous Squamous-Cellef cacy Squamous-Cell results Carcinoma Carcinomaof LIBTAYO … A look at a A Patient inA PhasePatient 1 Studyin Phase 1 Study …in this 62-year-old male.* cSCC patient case‡ The ef cacy and safety of LIBTAYO was evaluated in a combined analysis of two open-label, uncontrolled studies: Study 1423 (N=26) and Study 1540 (N=137).§

The following case is an example of a patient treated with LIBTAYO during one of the studies and the visible changes in external cSCC lesions 3 Following 6 weeks of that resulted. It may not be representative of all At baseline patients. treatment with LIBTAYO

* Patient from the Phase 1 study (Study 1423). Not representative of all patients.

Consider LIBTAYO for your patients with metastaticBaseline orBaseline locally advanced cSCC. Week 6 Week 6 B Patient inB PhasePatient 2 Studyin Phase 2 Study Tumour responses demonstrated with LIBTAYO, based on combined analysis from Study 1423 and Study 15401§¶

Ef cacy Endpoints†† Metastatic CSCC (N=75) Locally advanced CSCC (N=33) Combined CSCC (N=108) Con rmed Objective Response Rate (ORR, primary endpoint) ORR (%)‡‡ 95% CI 46.7% (35.1%, 58.6%) 48.5% (30.8%, 66.5%) 47.2% (37.5%, 57.1%) Complete response rate (CR)§§ 5.3% 0% 3.7% Partial response rate (PR) 41.3% 48.5% 43.5%

Adapted from LIBTAYO Product Monograph1

LIBTAYO (cemiplimab) is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. LIBTAYO has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for LIBTAYO, please refer to Health Canada’s Notice of Compliance withBaseline conditionsBaseline - drug products website. Marketing authorization withWeek conditions 8 Week is 8 based on tumour response rate and durability of response. An improvement in overall survival (OS) or progression-free survival (PFS) has not yet been established in this single-arm study. Figure 1. EffectFigure of 1. Cemiplimab Effect of Cemiplimab in Patients in with Patients Advanced with AdvancedCutaneous Cutaneous Squamous-Cell Squamous-Cell Carcinoma. Carcinoma. Panel A showsPanel a A 62 shows‑year‑ olda 62 patient‑year‑old at patientbaseline at and baseline after 6and weeks after of 6 treatment weeks of treatmentwith cemiplimab. with cemiplimab. Panel B shows Panel an B shows an Clinical use: • Infusion-related reactions83‑year‑old patient, who hadadvanced undergone cSCC. Studymultiple 1540: surgeries Phase 2, open-label, for cutaneous ¶ Results squamous are presented‑cell carcinoma, as a combined at baseline analysis ofand 83‑year‑old patient,multi-center who had study undergone in 137 patients multiple with metastatic surgeries for26 cutaneous cSCC patients squamous from ‑Studycell carcinoma, 1423 and at82 baseline and The safety and ef cacy of LIBTAYO in pediatric • Fertility after 8 weeks of treatment with cemiplimab. patients have not been established. • Pregnant and nursing women after 8 weeks of cSCCtreatment or locally with advanced cemiplimab. cSCC. Both studies patients from Study 1540. Contraindications: • Elderly excluded patients with autoimmune disease †† Median duration of follow-up: metastatic cSCC: • Hypersensitivity to LIBTAYO or any ingredient in the • Driving or operating machinery that required systemic therapy with 8.1 months; locally advanced cSCC: 10.2 months; formulation or component of the container immunosuppressant agents within 5 years; history combined cSCC: 8.9 months. For more information: ness of theness data of theand data theof fidelityandsolid theorgan offidelity transplant; the studies of prior the treatmenttostudies imaging with to ‡‡ imagingstudies. For patients studies.Results with ofmetastaticResults whole-body ofcSCC whole-body without imaging imaging 17 Relevant warnings and precautions: Please consult the LIBTAYOthe Product protocols. Monographthe protocols. at anti-PD-1/PD-L1 or other immune checkpointwere evaluated wereexternally evaluated according visible according targetto RECIST, lesions, to RECIST,versionORR was 1.1. version 1.1.17 • Risks of solid organ transplant rejection http://products.sano .ca/en/libtayo.pdf for important inhibitor therapy; infection with HIV, hepatitisIn the B or phase determined 2 study, by digitalResponse medical Evaluation photographs Criteria in • Immune-mediated adverse reactions including: information relating to adverse reactions, drug hepatitis C; ECOG performance score ≥ 2; or In Solidthe phaseTumors (RECIST2 study, 1.1). digital For patients medical with photographs Assessments - Pneumonitis interactions, and dosing information whichAssessments have not anogenital SCC or SCC arising on the dryof redthe lip skinof externally thewere skin evaluatedvisible were target evaluated accordinglesions (locally according to advanced protocol- to protocol- been discussed in this piece. The Product Monograph 1 - Colitis In both studies,In both studies,the patients(vermilion). the patientswere Patients assessed were received assessed for LIBTAYO a specified3 formg/kg a specified compositecSCC and metastaticcomposite response cSCC), response criteria. ORR was determined criteria.Confirma Confirma- - - Hepatitis is also available by calling us at 1-800-589-6215. every 2 weeks for 48 or 96 weeks or 350 mg every by a composite endpoint that integrated ICR responseresponse to cemiplimab to cemiplimab 3every weeks for8 weeks 54 weeks,every 8by except weeks means one bypatient of means tory in Study imagingof toryassessments imagingstudies of wereradiologicstudies obtained datawere (RECIST obtained no 1.1) less and than no less than - Endocrinopathies (hypothyroidism, cSCC: cutaneous squamous cell carcinoma 1 hyperthyroidism, hypophysitis, adrenal ‡ Patients from the pivotal trials, not representative 1423 who received LIBTAYO 1 mg/kg every digital medical photography (WHO criteria). insuf ciency, type 1 diabetes mellitus) of all patient cases. 2 weeks, not an indicated dosing for LIBTAYO. All §§ Only included patients with complete healing of § Study 1423: Phase 1, open-label, multi-center patients receivedn engl LIBTAYO j med as379;4 an IV nejm.orginfusion over July prior26, 2018 cutaneous involvement; locally advanced 345 - Skin adverse reactions 30 minutes until unequivocaln engl j medprogression 379;4 ofnejm.org cSCC patientsJuly 26, in 2018 study 1540 required biopsy to 345 - Nephritis study in 397 patients with a variety of advanced solid tumours - including 16 patients with disease, unacceptableThe toxicity New or England completion Journal of ofconfirm Medicine complete response. - Other potential immune-mediated adverse metastatic cSCC and 10 patients with locally planned treatment. Tumour responseThe assessments New England Journal of Medicine reactions DownloadedDownloaded from nejm.org from at nejm.org MCGILLwere at performed UNIVERSITYMCGILL every UNIVERSITY 8 weeks. LIBRARY LIBRARY on November on November22, 2018. For 22, personal2018. For use personal only. No use other only. uses No otherwithout uses permis withoutsion. permis sion. Copyright Copyright© 2018 Massachusetts © 2018 Massachusetts Medical Society. Medical All Society. rights reserved.All rights reserved. References: 1. LIBTAYO Product Monograph. Sanofi-Aventis Canada Inc. April 10, 2019. 2. Midgen MR et al. NEJM 2018; 379:341-51. 3. Data on file. Sanofi Genzyme Canada Inc.

LIBTAYO® and Sanofi Genzyme logos are trademarks of Sanofi , used under license by sanofi -aventis Canada Inc. © 2020 Sanofi Genzyme, a Division of sanofi -aventis Canada Inc. All rights reserved. SACA.LIB.20.05.0173E

LIB-20-402 Journal Ad 1-8-125x10-875_E12.indd 1 2020-09-08 1:36 PM CANO/ACIO 2020

Continuing Nursing Play the Virtual Scavenger Hunt! Education (CNE) There are many ways to earn points including: This event is approved for a maximum • Explore our exhibit hall and engage with sponsors of 9.75 hours of accredited continuing • Attend as many sessions as possible! nursing education by the Continuing Nursing • Earn additional points by attending Sponsored Symposia, Annual General Meeting, Education (CNE) Office, Ingram School of Award Ceremony, Keynote and Lectureship Sessions. Nursing, McGill University. Claim your points through the Gamification section of the platform. Gamifications Codes are hidden throughout the platform with the most points in the Cet événement est approuvé pour un Exhibit Hall and Poster Hall. maximum de 9.75 heures de formation HINT: Talk to our lovely Sponsors and Exhibitors! continue accréditées par le Bureau de la formation continue en sciences infirmières TOP 10 POINT EARNERS RECEIVE INCREDIBLE PRIZES FROM LOOK GOOD FEEL BETTER: (FCSI) de l’École des sciences infirmières #1 Place: La Roche Gift Basket Ingram de l’Université McGill. #2 Place: La Roche Gift Basket #3 Place: John Frieda Hair Beauty Gift Basket #4–10 Places: PUR Cosmetic Gift Set Scavenger Hunt Ends: Sunday, November 8th at 3:00 PM EST. Winners will be announced at the Closing Remarks. GAMIFICATION SPONSOR:

AMG_126386_XGEVA_PrCa_JA_16-9_EN_081020.pdf 1 2020-10-08 3:07 PM

Indication and clinical use: - XGEVA® (denosumab) is indicated for reducing the risk of developing skeletal-related events (SREs) in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, When bone metastases from non-small cell lung cancer, and other solid tumours. - XGEVA is not indicated for use in pediatric patients other than skeletally mature adolescents (aged 13–17 years) with giant cell tumour of bone. prostate cancer put Contraindications: XGEVA is contraindicated in patients with pre-existing hypocalcemia, which must be corrected prior to 1 initiating therapy. his bones at risk Most serious warnings and precautions: Osteonecrosis of the jaw (ONJ): In clinical trials, the incidence of ONJ was higher with longer duration of exposure. In patients with risk factors for ONJ, an individual beneﬁt-risk assessment should be performed before initiating therapy with XGEVA. An oral exam should be performed, and a dental exam with appropriate preventive dentistry is recommended prior to treatment with XGEVA, especially in patients with risk factors for ONJ. Avoid invasive dental procedures while receiving XGEVA. In patients who develop ONJ during treatment with XGEVA, a temporary interruption of treatment should be considered based on individual beneﬁt-risk assessment until the condition resolves. Other relevant warnings and precautions: - Do not use concurrently with Prolia®. - Do not use concurrently with bisphosphonates.

C - Hypocalcemia has been reported (including severe symptomatic hypocalcemia and fatal cases). - Caution on risk of hypocalcemia and accompanying increases in parathyroid hormone in patients with M renal impairment.

Y - Clinically signiﬁcant hypercalcemia has been reported in XGEVA-treated patients with giant cell tumour of bone and in patients with growing skeletons weeks to months following treatment discontinuation. CM - Skin infections. MY Take on his risk of SREs. - Hypersensitivity reactions, including anaphylaxis. CY ® 1 - Atypical femoral fractures.

CMY - Multiple vertebral fractures, not due to bone metastases, may occur following discontinuation of Take action with XGEVA . treatment with XGEVA, particularly in patients with risk factors such as osteoporosis or prior fracture. K - Avoid pregnancy and use contraception during treatment and for at least 5 months after the last dose of XGEVA. XGEVA® demonstrated superiority vs. zoledronic acid (ZA) in reducing the risk of developing first - Breastfeeding. †,1,2 and subsequent SREs* in patients with bone metastases from CRPC: For more information: • Risk of developing SREs reduced by 18% vs. ZA (mean number of SREs per patient: 0.52 vs. 0.61; Please consult the Product Monograph at http://www.amgen.ca/Xgeva_PM.pdf for a full list of indications RR: 0.82; 95% CI: 0.71–0.94; superiority p-value:‡ p=0.0085; secondary endpoint) and information on conditions of clinical use, and important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed here. The Product Monograph can also be obtained by calling Amgen Medical Information at 1-866-502-6436.

SRE: skeletal-related event; CRPC: castrate-resistant prostate cancer; RR: rate ratio; CI: confidence interval; SC: subcutaneous; IV: intravenous References: *SREs were defined as pathological fracture, radiation therapy to bone, surgery to bone, and spinal cord compression.1 1. XGEVA Product Monograph. Amgen Canada Inc. June 14, 2019. 2. Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone †Results of a Phase 3, randomized, double-blind, double-dummy, active-controlled study. Patients with CRPC and bone metastases (n=1,901) received either 120 mg XGEVA SC Q4W (once every 4 weeks) (n=950) or 4 mg ZA IV Q4W (n=951). The metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377(9768):813–822. primary outcome measure was to demonstrate non-inferiority of time to first on-study SRE as compared to ZA. The secondary outcome measures were superiority of time to first on-study SRE and superiority of time to first and subsequent SREs.2 ‡p-value adjusted for multiplicity.1 22

Program

CONFERENCE DAY 1: Friday, November 6, 2020 All times listed in Eastern Standard Time (EST) 5:30pm – 6:30pm ABSTRACTS: LEADERSHIP Adventures in Quality Improvement: Lessons and Experiences with Implementing a Frailty Morgan Stirling & Allison Wiens Screening and Deprescribing Process at CancerCare Manitoba 6:45PM – 7:00pm OPENING REMARKS Reanne Booker & Marie Marques 7:00PM – 7:45PM CANO AWARDS OF EXCELLENCE CEREMONY 7:45PM – 9:00PM Exhibit Hall, Networking & Poster Viewing

CONFERENCE DAY 2: Saturday, November 7, 2020 All times listed in Eastern Standard Time (EST) 8:30AM – 5:00PM Exhibit Hall, Networking & Poster Viewing BD SPONSORED SYMPOSIUM 9:00AM – 9:45AM Mikaela Olsen Limiting Your Exposure to Hazardous Drugs, and How to Advocate for Proper PPE JANSSEN SPONSORED SYMPOSIUM 9:00AM - 9:45AM Chair: Michelle Forman Kari Holm & Suzanne Rowland Integrating Subcutaneous Daratumumab Into Clinical Practice in Canada 10:00AM – 11:00AM ABSTRACTS: NURSING PERSPECTIVES 10:00AM – 10:20AM An interpretive Description of Moral Distress in Oncology Nursing Brenda Peters-Watral An Exploration of Healthcare Provider Work-Related Grief and 10:20AM – 10:40AM Allison Pedersen Strategies for Moving Through it Experience of Oncology Nurses and Cancer Survivors During Cancer 10:40AM – 11:00AM Treatment Transition From Oncology Teams to Primary Care Providers Manon Lemonde Teams 11:00AM – 12:00PM Exhibit Hall, Networking & Poster Presentations 11:00AM – 12:00PM ABSTRACT: SYMPTOM MANAGEMENT 11:00AM – 11:20AM Improving Pleural Effusion Management—The 11 Vic Experience Stephanie Bickford Causes, Consequences, and Management of Persistent Hiccups in 11:20AM – 11:40AM Susan E McClement Advanced Cancer Patients Introducing Telepractice Oncology Nurse for the Provision of Remote 11:40AM – 12:00PM Suganya Vadivelu Cancer Symptom Management Support KEYNOTE ADDRESS 12:05PM – 12:55PM Chair: Senz Hamilton Sally Thorne, RN, PhD, FAAN, FCAHS Nursing in Uncertain Times: The Art of Being a “Nuisance” 1:00PM – 2:00PM ABSTRACTS: PATIENT EMPOWERMENT Exploring Cancer Patients’ Perceptions of Accessing and Experience Katherine Mohsen & 1:00PM – 1:20PM with Using the Educational Material in the Opal Patient Portal Andréa Maria Laizner Processes of Treatment Decision Making Among Older Adults with 1:20PM – 1:40PM Fay J. Strohschein Colorectal Cancer: Implications for Oncology Nursing Practice 1:40PM – 2:00PM Who is Your SDM? Empowering Nurses to Engage in the Conversation Erin Fess 1:00PM – 2:00PM ELVIUM LIFE SCIENCES FOCUS GROUP (By Invitation Only) 1:00PM – 2:00PM MYLAN FOCUS GROUP (By Invitation Only) HELENE HUDSON LECTURESHIP & AWARD PRESENTATION (SPONSORED BY CANO/ACIO) 2:05PM – 2:55PM Chair: Karen Janes Edith Pituskin Now and the Twenty-First Century: Special Issues in Oncology Patients and Oncology Nursing

23 CANO/ACIO 2020 Program

CONFERENCE DAY 2: Saturday, November 7, 2020 All times listed in Eastern Standard Time (EST) ABSTRACTS: MODEL OF CARE 3:00PM – 3:30PM Assessing and Documenting Complementary and integrative Medicine at a Provincial Cancer Lynda G. Balneaves Agency ANNUAL CANO AND CAPO JOINT SYMPOSIUM Chair: Samantha Scime 3:45PM – 4:30PM Carmen G. Loiselle, George Lhermie Meeting the Needs of Individuals on Oral Anti-cancer Therapies: the Convergence of Research, Clinical and Patient Perspectives 4:30PM – 5:00PM Exhibit Hall, Networking & Poster Presentations 5:00PM – 6:00PM COVID & CANCER Reanne Booker & Christine Maheu 6:05PM - 7:15PM CANO/ACIO ANNUAL GENERAL MEETING (Members Only Session)

CONFERENCE DAY 3: Sunday, November 8, 2020 All times listed in Eastern Standard Time (EST) 8:30AM – 5:00PM Exhibit Hall, Networking & Poster Viewing ASTRAZENECA CANADA SPONSORED SYMPOSIUM 9:00AM – 9:45AM Dr. Carolyn Owen & Nicole Dunse Evolution of BTK inhibitors in CLL and Management of the Associated Side Effects LEO PHARMA SPONSORED SYMPOSIUM 9:00AM – 9:45AM Vanessa Higgins-Nogareda Cancer Associated Thrombosis: Role of the Nurse INTERNATIONAL WORKSHOP (Board Sponsored) Maurene McQuestion, Margaret Fitch, 10:00AM – 10:45AM Chair: Maurene McQuestion Reanne Booker, Tayreez Mushani 11:00AM – 12:00PM ABSTRACTS: KNOWLEDGE TRANSLATION How Can Dynamical Neurofeedback Help Cancer Survivors with Persistent Symptoms: Marian Luctkar-Flude Current Evidence and Therapy Demonstration 11:00AM – 12:00PM ASTRAZENECA AND MERCK FOCUS GROUP (By Invitation Only) 11:00AM – 12:00PM JAZZ PHARMACEUTICALS FOCUS GROUP (By Invitation Only) 12:00PM – 12:25PM Exhibit Hall, Networking & Poster Presentations CLINICAL LECTURESHIP AND AWARD (Sponsored by Merck) Chair: Karen Janes 12:30PM – 1:20PM Virginia Lee Good Clinical Practice in Cancer Research Trials: What Does it Mean for the Role of the Oncology Nurse? 1:30PM – 2:00PM RAPID FIRE PRODUCT PRESENTATIONS 2:05PM – 2:50PM ABSTRACTS: LEADERSHIP Strengthening Oncology Nurses’ Collective Voice in Optimizing Care of Older Adults with Fay J. Strohschein, Martine Puts, Cancer and Their Caregivers: Contributing to an International Position Statement Lorelei Newton, Rana Jin 2:55PM – 3:40PM SPECIAL INTEREST GROUP PRESENTATIONS Trading Cocktails with Friends for Chemo Cocktails—Coming of Age 2:55PM – 3:10PM Meghan MacMillan with Cancer Meeting the Unique Needs of Cancer Survivors: Tips from the Carrie MacDonald-Liska, 3:10PM – 3:25PM CANO Survivorship Manual Karine Bilodeau 3:25PM – 3:40PM Immuno-Oncology Nursing…Now & Forever Leslie Marvell, Marcie Flynn-Post CANO/CANADIAN CANCER SOCIETY JOINT SYMPOSIUM Chair: Reanne Booker Suzanne Bays, Laura Burnett & 3:45PM – 4:30PM Bridging the Gap Between Clinic and The Community: How to Support Patients and Their Reanne Booker Caregivers Living with Advanced Cancer 4:30PM – 5:00PM CLOSING REMARKS Reanne Booker

The only CDK4/6 inhibitor dosed twice daily, every day.1,2*†

When is it time to consider PrVerzenioTM? Verzenio is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer1 • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. • as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy regimen should have been administered in the metastatic setting, and at least one should have contained a taxane. Pam‡ Anna‡

She has not received systemic She has recurred on adjuvant therapy for advanced disease1 endocrine therapy and has not received chemotherapy in the metastatic setting1

Pam’s Disease Anna’s Disease Characteristics:‡ Characteristics:‡ • HR+, HER2- metastatic breast cancer1 • HR+, HER2- advanced breast cancer1 • Postmenopausal1 • Experienced disease progression following • Measurable disease1 endocrine therapy • Liver metastases3 • Primary resistance to endocrine therapy1 • Metastatic recurrent with treatment-free interval • Negative progesterone receptor status1,4 >12 months after receiving endocrine therapy in the neoadjuvant setting1,3 In patients like Pam, consider Verzenio in combination with In patients like Anna, consider Verzenio in combination with an aromatase inhibitor as an initial endocrine-based therapy. fulvestrant following endocrine therapy.

Consult the Product Monograph at http://pi.lilly.com/ca/verzenio-ca-pm.pdf for important information on: • Contraindications regarding hypersensitivity to Verzenio or to any of the ingredients. • Most serious warnings and precautions including venous thromboembolism. • Other relevant warnings and precautions regarding diarrhea, neutropenia, interstitial lung disease/pneumonitis, hepatoxicity, infections, monitoring of complete blood counts, caution when driving or operating machinery, fertility impairment in males, usage during pregnancy, and usage in nursing women. • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions. The Product Monograph is also available by calling us at 1-800-545-5972.

* Clinical significance has not been established. † Comparative clinical significance unknown. ‡ Hypothetical patient profile. May not be representative of all patients.

References: 1. VerzenioTM Product Monograph. Eli Lilly Canada Inc. September 23, 2019. 2. Eli Lilly Canada, Attestation Letter: VerzenioTM (abemaciclib), April 10, 2019. 3. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35:3638-3646. 4. Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884. VerzenioTM is a mark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates. © 2019 Eli Lilly and Company. All rights reserved. PP-AL-CA-0064 CANO/ACIO 2020

Abstract Posters

Abstract Abstract Title Presenters Numer Targeting Malnutrition Risk: A Collaborative Approach to Early Identification and P-01 Vondell Klein, Vivian Kong Intervention of Patients in a Community Hospital’s Cancer Care Clinic Breast Cancer Survivorship Program: Implementing a Follow-Up Care Model in a P-03 Jane Li Community Hospital Cancer Clinic P-04 A Scoping Review of Palliative Psychotherapy in Adult Patients with Advanced Leukemia Argin Malakian A Nurse Navigator’s Experience in Supporting Indigenous Patients and Families Living with Tara Abdul-Fatah, Carolyn Roberts, Gwen R P-09 Cancer Barton P-11 Bile, Worm, Cell, Me: a Brief Sociocultural History of Cancer and Identity Jennifer Marie Lior Stephens Getting Ready for a New Normal: a Formal Education Program to Establish and Maintain Kaminiben Patel, Vanessa Loiacono, Laura P-15 Competency on Immune Effector Cell Therapy Olmi On-Demand Respite Care: A Protocol to Develop a Proof-Of-Concept of a Smartphone P-17 Aimee Castro Application for Coordinating Nursing Respite Care Services for Families with Cancer Enhancing Nurses’ Confidence Levels in Managing Hypersensitivity Reactions Among P-18 Rosemarie Rivera Oncology Population P-19 Indigenous Voices 2: Improving Care for Indigenous Patients and Families Allison Pedersen, Holly Prince Informing Enhanced Nursing Care in Pediatric Oncology: Did You Say Something About a P-20 Jill M.G. Bally New Easy-To- Use Intervention? P-21 Nursing in The Era of Genomics: A New Frontier Lindsay Carlsson Zoe E.M Evans, Kayla Madsen, Katherine Lee, P-29 The Role of the Allogeneic Transplant Nurse Practitioner in the Outpatient Setting Gertrude Trinh, Peggy Chen Communicating Effectively: Working with Patients and Their Families Across the Cancer P-30 Samantha Scime Continuum P-32 Ambulatory Oncology Nurses Perspectives of Patient-Reported Outcomes in Alberta Danielle L Moch Using Patient Reported Outcomes (Pros) in Ambulatory Cancer Care: Using an Unfolding P-33 Case Study to Examine the Role of the Oncolgy Nurse and the Potential for Improvements Linda Watson, April Hildebrand in Practice P-34 La Télésanté dans la Pratique des Infirmières Pivots en Oncologie (IPO) Josee Beaudet, Sabrina Lapointe Utilizing Middle-Range Nursing Theory to Improve the Delivery of Supportive Care P-38 Kylie Teggart Resources for Patients with Head and Neck Cancers P-39 Catheter Lock Solutions: The Debate, the Triple Threat and the Solution Karen Mueller Pan-Canadian Oncology Symptom Remote Support and Triage (COSTaRS) Practice Guides P-40 Dawn Stacey Version 2020 Breast Cancer Survivor Experiences with a Dynamical Neurofeedback Intervention: P-41 Marian Luctkar-Flude Preliminary Results of a Qualitative Descriptive Study Evaluating the Effectiveness of a Learning Pathway to Guide Nurses Being Orientated to P-47 Cheryl Page the Hematopoietic Stem Cell Transplant Coordination Role Cristina Emanuele, Meghan MacMillan, P-49 Adolescent and Young Adult Cancer Survivors Preferences in Survivorship Care Jonathan Avery

27 CANO/ACIO 2020 Abstract Posters

Abstract Abstract Title Presenters Numer The Road to Car-T: Understanding the Process, Administration, and Patients’ Lived P-50 Jeanne Niskiewicz Experiences The Contribution of Illness Perception, Meaning in Life, and Coping to Anxiety and P-51 Hee Sun Kim, Samantha J Mayo Depression in Advanced Cancer Patients Undergoing Chemotherapy P-52 The Clinical Nurse Specialist Role in Oncology Verna Cheung, Maurene McQuestion, Rana Jin A Phase IV, Real World Observational Study on the Use of Netupitant/Palonosetron P-53 (NEPA®) for the Prevention of CINV in Patients Receiving Highly Emetogenic Chemotherapy Henry Conter (HEC) Over Multiple Cycles Presence and Severity of Perceived Cognitive Difficulties Across Cancer Types: Findings P-54 Samantha J Mayo From a Large Retrospective Analysis Oncology Nurses’ Constructions of Inequitable Access to Oncology Care Among Indigenous P-55 Tara C Horrill Peoples Optimization and Standardization of the Administration of Intravenous Chemotherapy and Josee Beaudet, Luisa Luciani Castiglia, Renata P-57 Biotherapy in Quebec: a Collaborative Approach Benc, Dencia Jean-Paul, Vanessa Palma Is Patient Activation Associated with Perception and Satisfaction with Information P-58 Hee Sun Kim, Samantha J Mayo Provision, Symptom Distress, and Quality of Life in Lung Cancer Patients? P-59 Tailored Training for Hematology/Oncology Nurses Tracy Regimbald Tracy L. Powell, Leah K. Lambert, Fay J. Stepping Into Graduate Studies: Exploring How Graduate Education Can Impact Your P-60 Strohschein, Tara C Horrill, Billy Vinette, Amina Practice in Oncology and Patient Care. Silva, Kristen R Haase Multidisciplinary Teams in Radioactive Iodine-Refractory (RAI) Differentiated Thyroid Cancer (RDTC): Analysis of the Canadian Patient Support Program (PSP) for Patients’ (PTS) P-62 Xuan Kim Le Outcomes, Such As Progression Free Survival (PFS) and Objective Response Rate (ORR), and Treatment Patterns with Lenvatinib (LEN) Understanding the Lived Experience of Inpatient Cancer Patients Recieving Care From a P-64 Gayatre a Maharaj Specialized Oncology Nurse Practitioner: A Research Proposal Embracing Diversity: Awareness Events Based on Listening to Patients’ Experiences and P-67 Jennifer Deering Addressing Unmet Needs Head and Neck Cancer Surgery: Patient and Staff Perspective On Pre-Operative Stephanie Hubbard, Erin S MacDonald, Alison P-70 Educational Needs MacDonald New Patient Intake Assessment at BC Cancer Victoria: From Problem Centered to Patient P-71 Cloé Bailly Vignola Edwards, Aimee Morrow Centered Care Cardio-Oncology Screening and Assessments in Patients Referred for Autologous Bone P-73 Tara Reber Marrow Transplantation

JOIN US AT THE 33RD ANNUAL CANO/ACIO CONFERENCE

Niagara Falls, Ontario October 22-25, 2021 Niagara Falls Marriott on the Falls & Scotiabank Convention Centre

I Am, I Will: A Call to Action Je suis et je vais : Appel à l’action